Sonoma to receive $75M up front incl. $45M in cash & $30M in equity investment, ~$45M in development milestones. Both parties will equally co-fund R&D for all potential products & share future commercial expenses & profits
Both companies will jointly research and develop Treg cell therapies for UC, CD & two other indications with a Regeneron option for the 5th indication. Regeneron to get an option to lead late-stage development and commercialization on all products globally while Sonoma holds rights to co-promote in the US & will also hold full ownership of SBT-77-7101, and other programs in development
The collaboration will combine Regeneron’s technology & clinical expertise with Sonoma Bio’s Treg platform & Treg research enterprise to develop therapies
Ref: Businesswire | Image: Sonoma
Related News:- Regeneron and Sanofi Report P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease
